Antifungal drugs: New insights in research & development.
Pharmacol Ther
; 195: 21-38, 2019 03.
Article
en En
| MEDLINE
| ID: mdl-30347212
ABSTRACT
The need for better antifungal therapy is commonly accepted in view of the high mortality rates associated with systemic infections, the low number of available antifungal classes, their associated toxicity and the increasing number of infections caused by strains with natural or acquired resistance. The urgency to expand the range of therapeutic options for the treatment of fungal infections has led researchers in recent decades to seek alternative antifungal targets when compared to the conventional ones currently used. Although new potential targets are reported, translating the discoveries from bench to bedside is a long process and most of these drugs fail to reach the patients. In this review, we discuss the development of antifungal drugs focusing on the approach of drug repurposing and the search for novel drugs for classical targets, the most recently described gene targets for drug development, the possibilities of immunotherapy using antibodies, cytokines, therapeutic vaccines and antimicrobial peptides.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Micosis
/
Antifúngicos
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Pharmacol Ther
Año:
2019
Tipo del documento:
Article
País de afiliación:
Brasil